UTHSCSA Faculty Profiles v1.0

Wagner, Brent T

School of Medicine
(210) 567-4700

Brent Wagner, M.D., is a graduate of the University of New Mexico School of Medicine (1999). He has a master`s degree (M.S.) in Biomedical Sciences from UNM (1995). He is now a certified specialist in Internal Medicine and Nephrology and currently the Director of the clinical nephrology training program.
For two decades, his research has focused on renal development and mechanisms implicated in kidney injury. This work contributed to the better understanding of the role of metanephric mesenchymal cells as a precursor to mesangial cells and the effects of platelet-derived growth factor isoforms in renal development. His discoveries were that reactive oxygen species and Nox4 (NADPH oxidase 4) are key mediators of glomerular cell precursor migration in the embryonic kidney. He was the first scientist who successfully demonstrated the differential effects of PDGF and PDGF receptor isoforms on mesenchymal cell migration and proliferation, two key biological processes required for the formation of the adult kidney.
Then, as a clinician, his attention was drawn to patients with impaired kidney function exposed to gadolinium-based contrast agents during magnetic resonance imaging and the subsequent development of terminal and wide-spread fibrosis. This compelled him to initiate a new and original line of research founded on a relatively obscure/rare pathology at that time referred to as `nephrogenic? systemic fibrosis. After establishing the first animal model of gadolinium-induced systemic fibrosis, Dr. Wagner`s work characterized the fibrotic processes taking place in each of the affected organs. These studies established, for the first time, the importance of oxidative stress (Nox4), inflammatory chemokines, and bone marrow-derived fibrocytes in skin, liver, and heart lesions in rats and mice that underwent bone marrow transplant from `tagged? donors. Since, his laboratory is also involved in preclinical studies testing the bioefficacy of a new oral drug with the potential to prevent or reduce the manifestations of gadolinium-associated organ injury in experimental animal models.

9/2017 - Present Associate Professor with Tenure and Associate Professor of Medicine (Nephrology) University of Texas Health Science Center at San Antonio, Medicine, San Antonio, TX
5/2010 - Present Director, Clinical Nephrology Training Program and Director University of Texas Health Science Center at San Antonio, Medicine, San Antonio, TX
1/2008 - Present Staff Physician South Texas Veterans Health Care System, Medicine, San Antonio, TX
7/2005 - Present Staff Physician University Hospital System, Medicine, San Antonio, TX